A study in children with simultaneous allergy to multiple foods on the efficacy of anti-IgE treatment showed that the group treated with omalizumab was significantly more likely to reach > 2 g protein of the culprit allergen source in food challenge in at least more than two of the food allergies compared to placebo [1, 64]. This evidence concerns the gene IGHE and food allergy.